Debt-to-equity of Arcadia Biosciences, Inc. from 31 Mar 2016 to 31 Dec 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Arcadia Biosciences, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2016 to 31 Dec 2024.
Arcadia Biosciences, Inc. Debt-to-equity for the quarter ending 31 Dec 2024 was 61%, a 1.9% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Arcadia Biosciences, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2024	61%	+1%	+1.9%	31 Dec 2024
Q3 2024	52%	-3%	-5.4%	30 Sep 2024
Q2 2024	52%	+2%	+4.6%	30 Jun 2024
Q1 2024	52%	+8%	+19%	31 Mar 2024
Q4 2023	60%	+27%	+81%	31 Dec 2023
Q3 2023	55%	+20%	+58%	30 Sep 2023
Q2 2023	50%	+12%	+31%	30 Jun 2023
Q1 2023	44%	-4%	-8.2%	31 Mar 2023
Q4 2022	33%	-21%	-39%	31 Dec 2022
Q3 2022	34%	-25%	-42%	30 Sep 2022
Q2 2022	38%	-37%	-49%	30 Jun 2022
Q1 2022	48%	-46%	-49%	31 Mar 2022
Q4 2021	54%	-82%	-60%	31 Dec 2021
Q3 2021	59%	-155%	-72%	30 Sep 2021
Q2 2021	75%	-131%	-64%	30 Jun 2021
Q1 2021	94%	-114%	-55%	31 Mar 2021
Q4 2020	137%	-148%	-52%	31 Dec 2020
Q3 2020	214%	+8%	+4.1%	30 Sep 2020
Q2 2020	206%	+22%	+12%	30 Jun 2020
Q1 2020	208%	+6%	+2.8%	31 Mar 2020
Q4 2019	284%	+80%	+39%	31 Dec 2019
Q3 2019	206%	-22%	-9.7%	30 Sep 2019
Q2 2019	184%	-41%	-18%	30 Jun 2019
Q1 2019	202%	-10%	-4.8%	31 Mar 2019
Q4 2018	204%	+40%	+25%	31 Dec 2018
Q3 2018	228%	+60%	+36%	30 Sep 2018
Q2 2018	225%	+60%	+37%	30 Jun 2018
Q1 2018	213%	+75%	+54%	31 Mar 2018
Q4 2017	164%	+46%	+39%	31 Dec 2017
Q3 2017	168%	+66%	+64%	30 Sep 2017
Q2 2017	165%	+72%	+78%	30 Jun 2017
Q1 2017	138%	+53%	+63%	31 Mar 2017
Q4 2016	118%			31 Dec 2016
Q3 2016	102%			30 Sep 2016
Q2 2016	92%			30 Jun 2016
Q1 2016	85%			31 Mar 2016

* An asterisk sign (*) next to the value indicates that the value is likely invalid.